PEG-Based CD47/PD-L1 Bispecific ADC for Tumor Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody-drug conjugates (ADCs) face challenges such as non-specific toxicity, narrow therapeutic windows, off-target binding, and difficulties in intratumoral distribution due to size and binding site barriers, as well as limitations in targeting PD-L1 and CD47 antigens on tumor cells.
Innovation Solution
A PEG-based bispecific antibody-drug conjugate is developed with site-specific conjugation to a bispecific antibody fragment, utilizing linkers that release cytotoxic drugs at tumor sites or within cells, enhancing tumor selectivity and reducing off-target effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional ADCs are used to target tumor cells, then cytotoxic efficacy is improved, but non-specific toxicity to healthy cells increases
Solution Approach 1:
The antibody is engineered to be bispecific, simultaneously targeting two different tumor antigens (PD-L1 and CD47) with different binding sites. This multi-functionality allows the ADC to recognize tumor cells through multiple pathways while maintaining selectivity, thereby improving cytotoxic efficacy without increasing non-specific toxicity to healthy cells.
Solution Approach 2:
The patent introduces site-specific conjugation technology that attaches cytotoxic drugs to specific locations on the antibody molecule (e.g., engineered cysteine residues or N-terminal glycines). This local quality control ensures uniform drug distribution and controlled release at the tumor site, maximizing cytotoxic efficacy while minimizing off-target effects through precise spatial control of drug delivery.
2Reliability
If ADC dosage is increased to achieve clinical efficacy, then tumor inhibition is improved, but maximum tolerated dose is approached resulting in narrow therapeutic window
Solution Approach 1:
The patent employs cleavable linkers that change their chemical properties in response to the tumor microenvironment (e.g., pH-sensitive, enzyme-sensitive, or redox-sensitive linkers). These parameter changes allow the cytotoxic drug to remain stable during circulation at lower doses while being activated specifically within the tumor, thereby improving tumor inhibition efficacy without proportionally increasing systemic toxicity and expanding the therapeutic window.
3Duration of action of stationary object
If ADC molecular size is increased to improve stability, then half-life is improved, but intratumoral distribution and penetration are worsened
Solution Approach 1:
The patent utilizes a single-chain antibody format that segments the traditional four-chain antibody structure into a more compact configuration. This segmentation reduces the overall molecular size and hydrodynamic radius of the ADC, improving its ability to penetrate deep into tumor tissue and distribute uniformly throughout the tumor mass, while the PEGylation component simultaneously extends circulation half-life through reduced renal clearance.
4Reliability
If ADC binds strongly to target antigen, then targeting specificity is improved, but binding site barrier prevents deep tumor penetration
Solution Approach 1:
The patent employs affinity-matured antibody variants with dynamically adjusted binding affinities for different targets. By optimizing the kinetic parameters (on-rate and off-rate) of antigen binding, the ADC can initially bind with high specificity to ensure target recognition, then utilize dissociation and rebinding events to progressively penetrate deeper into the tumor, overcoming the binding site barrier while maintaining targeting specificity.
Data Source
AI summary
An antibody-drug conjugate (ADC) especially PEG based bispecific antibody-drug conjugate (P-BsADC) includes antigen binding domains bonding to CD47 and PD-L1. A method for the preparation of the P-BsADC, a composition including the P-BsADC, and the use thereof in treating diseases.